Woodline Partners LP Reduces Stock Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Woodline Partners LP cut its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 14.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,014,015 shares of the biopharmaceutical company's stock after selling 327,106 shares during the period. Woodline Partners LP owned approximately 3.04% of Celldex Therapeutics worth $50,894,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. increased its position in shares of Celldex Therapeutics by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,881,995 shares of the biopharmaceutical company's stock worth $98,098,000 after acquiring an additional 12,213 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Celldex Therapeutics by 23.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock worth $89,890,000 after acquiring an additional 676,771 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Celldex Therapeutics by 50.8% during the fourth quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock worth $63,579,000 after acquiring an additional 847,264 shares in the last quarter. Deep Track Capital LP bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth about $38,919,000. Finally, Rock Springs Capital Management LP increased its position in shares of Celldex Therapeutics by 10.7% during the fourth quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company's stock worth $30,885,000 after acquiring an additional 118,404 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on CLDX shares. Canaccord Genuity Group assumed coverage on shares of Celldex Therapeutics in a research note on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective for the company. The Goldman Sachs Group reduced their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a report on Friday, May 9th. Morgan Stanley dropped their price target on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Finally, UBS Group reduced their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Trading Up 2.1%

Shares of NASDAQ:CLDX traded up $0.42 during mid-day trading on Thursday, reaching $20.37. The company had a trading volume of 538,144 shares, compared to its average volume of 895,651. The company's 50-day moving average price is $18.90 and its 200-day moving average price is $22.49. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $47.00. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -7.93 and a beta of 1.39.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $1.08 million. On average, research analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.